AMBU B Ambu A/S Class B

AMBU CAPITAL MARKETS DAY 2023

AMBU CAPITAL MARKETS DAY 2023

Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023.



On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark.

At the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the company’s new ZOOM IN strategy for delivering long-term sustainable double-digit revenue growth. This includes diving into the company’s strategic focus areas, its transformation program and providing a financial update on its long-term financial aspiration. Furthermore, the event will feature Q&A sessions as well as a product demonstration as the final item on the agenda.

All presentations and Q&As are held from 10:00-15:00 CET.

The product demonstration will run from 15:00-16:00 CET and will be for in-person attendees only.

The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website, .



SIGN UP FOR IN-PERSON ATTENDANCE


We encourage you to sign up for in-person attendance now. no later than Friday 3 March 2023.

Due to capacity constraints, please note that institutional investors, stock analysts and financial media are given in-person attendance priority to the event. Private investors are encouraged to follow the event online.



FOLLOW THE EVENT ONLINE


Ambu’s Capital Markets Day 2023 will be broadcasted live, and a video streaming link will be added to the Investor Relations site on the company’s website prior to the event.

Please note that online attendees will not be able to ask questions during the Q&A sessions. In addition, the product demonstration from 15:00-16:00 CET will not be livestreamed during the event. Instead, it will take place for in-person attendees only.

We look forward to seeing you at Ambu’s Capital Markets Day 2023.



Kind regards,

Ambu’s Investor Relations team



CONTACT

Investors

Nicolai Thomsen, Director, Investor Relations & Strategic Finance, ,

Media

Tine Bjørn Schmidt, Head of Corporate Communications, ,



Ambu A/S

Baltorpbakken 13

DK-2750 Ballerup, Denmark

Tel.:

CVR no.: 63 64 49 19





ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit .

Attachment



EN
07/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch